Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery

Bayer and Iambic collaborate to advance drug discovery with AI

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Iambic to participate in upcoming investor conferences

Iambic to Participate in April Investor Conferences

Scaling Multi-Modal and Multi-Task Transformers for Small Molecule Drug Discovery

San Diego NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations

IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC

Enchant v2: Pushing the Boundaries of Predictive Drug Discovery

A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)

NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

Enchant whitepaper: Breaking the data wall between lab and clinic

Multi-Modal and Multi-Task Transformer for Small Molecule Drug Discovery

JPM Healthcare Conference 2026 Company Presentation

Promise & Reality: Decoding AI’s Impact On Drug Development

From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery

Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development

Leveraging AI/ML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance

Predictive Drug Discovery with Enchant v2

Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at #WCLC25

Fireside chat at the KeyBanc Capital Markets Technology Leadership Forum

Video: Iambic CEO Tom Miller Interview at the NASDAQ MarketSite